These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers. Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553 [TBL] [Abstract][Full Text] [Related]
4. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)]. Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988 [TBL] [Abstract][Full Text] [Related]
6. Mutational profiling of colorectal cancers with microsatellite instability. Lin EI; Tseng LH; Gocke CD; Reil S; Le DT; Azad NS; Eshleman JR Oncotarget; 2015 Dec; 6(39):42334-44. PubMed ID: 26517354 [TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861 [TBL] [Abstract][Full Text] [Related]
9. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy. Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873 [TBL] [Abstract][Full Text] [Related]
10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
12. Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer. Takahashi Y; Sugai T; Habano W; Ishida K; Eizuka M; Otsuka K; Sasaki A; Takayuki Matsumoto ; Morikawa T; Unno M; Suzuki H Int J Cancer; 2016 Dec; 139(11):2493-501. PubMed ID: 27509333 [TBL] [Abstract][Full Text] [Related]
13. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226 [TBL] [Abstract][Full Text] [Related]
14. Mutational and expressional analysis of SMC2 gene in gastric and colorectal cancers with microsatellite instability. Je EM; Yoo NJ; Lee SH APMIS; 2014 Jun; 122(6):499-504. PubMed ID: 24483990 [TBL] [Abstract][Full Text] [Related]
15. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216 [TBL] [Abstract][Full Text] [Related]
16. Subtyping of microsatellite instability-high colorectal cancer. Hu W; Yang Y; Qi L; Chen J; Ge W; Zheng S Cell Commun Signal; 2019 Jul; 17(1):79. PubMed ID: 31331345 [TBL] [Abstract][Full Text] [Related]
17. [Familial colorectal cancer type X: clinical, pathological and molecular characterization]. Ferreira S; Lage P; Sousa R; Claro I; Francisco I; Filipe B; Suspiro A; Chaves P; Rodrigues P; Albuquerque C; Nobre Leitão C Acta Med Port; 2009; 22(3):207-14. PubMed ID: 19686620 [TBL] [Abstract][Full Text] [Related]
18. Colorectal serrated pathway cancers and precursors. O'Brien MJ; Zhao Q; Yang S Histopathology; 2015 Jan; 66(1):49-65. PubMed ID: 25263173 [TBL] [Abstract][Full Text] [Related]
19. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden]. Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897 [TBL] [Abstract][Full Text] [Related]